BR112023013828A2 - 4-cloro-n-[2-[(4-clorofenil)metil]-3-oxo-1,2,4-tiadiazol-5-il]benzamida para uso na medicina - Google Patents
4-cloro-n-[2-[(4-clorofenil)metil]-3-oxo-1,2,4-tiadiazol-5-il]benzamida para uso na medicinaInfo
- Publication number
- BR112023013828A2 BR112023013828A2 BR112023013828A BR112023013828A BR112023013828A2 BR 112023013828 A2 BR112023013828 A2 BR 112023013828A2 BR 112023013828 A BR112023013828 A BR 112023013828A BR 112023013828 A BR112023013828 A BR 112023013828A BR 112023013828 A2 BR112023013828 A2 BR 112023013828A2
- Authority
- BR
- Brazil
- Prior art keywords
- benzamide
- chlorophenyl
- oxo
- chloro
- methyl
- Prior art date
Links
- WEDWLYRQKUTOAX-UHFFFAOYSA-N 4-chloro-n-[2-[(4-chlorophenyl)methyl]-3-oxo-1,2,4-thiadiazol-5-yl]benzamide Chemical compound C1=CC(Cl)=CC=C1CN1C(=O)N=C(NC(=O)C=2C=CC(Cl)=CC=2)S1 WEDWLYRQKUTOAX-UHFFFAOYSA-N 0.000 title abstract 2
- UDMBCSSLTHHNCD-UHFFFAOYSA-N Coenzym Q(11) Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(O)=O)C(O)C1O UDMBCSSLTHHNCD-UHFFFAOYSA-N 0.000 abstract 1
- 102000001253 Protein Kinase Human genes 0.000 abstract 1
- 230000003213 activating effect Effects 0.000 abstract 1
- UDMBCSSLTHHNCD-KQYNXXCUSA-N adenosine 5'-monophosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O UDMBCSSLTHHNCD-KQYNXXCUSA-N 0.000 abstract 1
- 229950006790 adenosine phosphate Drugs 0.000 abstract 1
- KXDAEFPNCMNJSK-UHFFFAOYSA-N benzene carboxamide Natural products NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037765 diseases and disorders Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 abstract 1
- 108060006633 protein kinase Proteins 0.000 abstract 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/433—Thidiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4891—Coated capsules; Multilayered drug free capsule shells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Endocrinology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Inorganic Chemistry (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB2100352.0A GB202100352D0 (en) | 2021-01-12 | 2021-01-12 | New methods |
| PCT/GB2022/050054 WO2022153042A1 (en) | 2021-01-12 | 2022-01-11 | 4-chloro-n-[2-[(4-chlorophenyl)methyl]-3-oxo-1,2,4-thiadiazol-5-yl]benzamide for use in medicine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112023013828A2 true BR112023013828A2 (pt) | 2023-10-03 |
Family
ID=74667674
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112023013828A BR112023013828A2 (pt) | 2021-01-12 | 2022-01-11 | 4-cloro-n-[2-[(4-clorofenil)metil]-3-oxo-1,2,4-tiadiazol-5-il]benzamida para uso na medicina |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20240082222A1 (https=) |
| EP (1) | EP4277625A1 (https=) |
| JP (1) | JP2024505143A (https=) |
| KR (1) | KR20230159375A (https=) |
| CN (1) | CN117320716A (https=) |
| AU (1) | AU2022208237A1 (https=) |
| BR (1) | BR112023013828A2 (https=) |
| CA (1) | CA3208099A1 (https=) |
| GB (1) | GB202100352D0 (https=) |
| IL (1) | IL304392A (https=) |
| MX (1) | MX2023008263A (https=) |
| WO (1) | WO2022153042A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11691954B2 (en) | 2019-10-18 | 2023-07-04 | Betagenon Ab | Formulations |
| WO2025027205A1 (en) * | 2023-08-03 | 2025-02-06 | Betagenon Ab | Treatment of cancer with the pdk inhibitor 4-chloro-n-(2-(4-chlorobenzyl)-3-oxo-2,3-dihydro-1,2,4-thiadiazol-5-yl)benzamide |
| WO2025252672A1 (en) * | 2024-06-03 | 2025-12-11 | Betagenon Ab | Use of tryptophan and metabolites thereof as biomarkers for treatment methods |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1625848A1 (en) * | 2004-08-10 | 2006-02-15 | Taro Pharmaceuticals North America, Inc. | Composition and method for enhanced delivery of 5,5-diphenyl barbituric acid |
| JP5982281B2 (ja) * | 2009-07-08 | 2016-08-31 | バルティック バイオ アーベー | 医薬として有用な化合物 |
| AU2011281381B2 (en) * | 2010-07-21 | 2015-07-16 | Novartis Ag | Salt and solvates of a tetrahydroisoquinoline derivative |
| KR20190009428A (ko) * | 2013-10-25 | 2019-01-28 | 안테씨프 바이오벤쳐스 투 엘엘씨 | 질병의 치료를 위한, 졸레드론산 또는 관련 화합물의 경구 투여용 조성물 |
| AU2018448511B2 (en) * | 2018-11-05 | 2025-07-03 | Betagenon Ab | Methods of treating diabetes in severe insulin-resistant diabetic subjects |
| US11691954B2 (en) * | 2019-10-18 | 2023-07-04 | Betagenon Ab | Formulations |
| GB201915094D0 (en) * | 2019-10-18 | 2019-12-04 | Balticgruppen Bio Ab | New formulations |
-
2021
- 2021-01-12 GB GBGB2100352.0A patent/GB202100352D0/en not_active Ceased
-
2022
- 2022-01-11 JP JP2023541948A patent/JP2024505143A/ja active Pending
- 2022-01-11 EP EP22701013.9A patent/EP4277625A1/en active Pending
- 2022-01-11 US US18/271,627 patent/US20240082222A1/en active Pending
- 2022-01-11 MX MX2023008263A patent/MX2023008263A/es unknown
- 2022-01-11 CN CN202280020127.2A patent/CN117320716A/zh active Pending
- 2022-01-11 BR BR112023013828A patent/BR112023013828A2/pt unknown
- 2022-01-11 AU AU2022208237A patent/AU2022208237A1/en active Pending
- 2022-01-11 CA CA3208099A patent/CA3208099A1/en active Pending
- 2022-01-11 WO PCT/GB2022/050054 patent/WO2022153042A1/en not_active Ceased
- 2022-01-11 KR KR1020237027428A patent/KR20230159375A/ko active Pending
-
2023
- 2023-07-11 IL IL304392A patent/IL304392A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2022208237A1 (en) | 2023-08-10 |
| CA3208099A1 (en) | 2022-07-21 |
| EP4277625A1 (en) | 2023-11-22 |
| KR20230159375A (ko) | 2023-11-21 |
| WO2022153042A1 (en) | 2022-07-21 |
| US20240082222A1 (en) | 2024-03-14 |
| CN117320716A (zh) | 2023-12-29 |
| AU2022208237A9 (en) | 2024-07-25 |
| JP2024505143A (ja) | 2024-02-05 |
| IL304392A (en) | 2023-09-01 |
| MX2023008263A (es) | 2023-09-12 |
| GB202100352D0 (en) | 2021-02-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112023013828A2 (pt) | 4-cloro-n-[2-[(4-clorofenil)metil]-3-oxo-1,2,4-tiadiazol-5-il]benzamida para uso na medicina | |
| BR112023005344A2 (pt) | Análogos de n-(2-(2,6-dioxopiperidin-3-il)-1,3-dioxoisoindolin- 5-il)arilsulfonamida substituídos como moduladores da proteína cereblon | |
| BR112021022796A2 (pt) | Inibidores de inflamassoma de nlrp3 | |
| PE20212154A1 (es) | Inhibidores de la proteina tirosina fosfatasa y metodos para usarlos | |
| BR0210291A (pt) | Compostos de sulfonamida substituìdos, processo para sua preparação e seu uso como medicamento para o tratamento de distúrbios do sistema nervoso central, obesidade e diabetes do tipo ii | |
| BR112020026125A8 (pt) | Compostos oligonucleotídeos superiores ou 5'-cap- trinucleotídeo e seus usos na estabilização de rna, expressão de proteínas e em terapia | |
| US20150018301A1 (en) | LRRK-2-Mediated Neuronal Toxicity | |
| BR9810920A (pt) | Modificação da forma de cristal de um derivado de n-fenil-2-pirimidinoamina, processos para sua fabricação e seu uso | |
| BR112022002683A2 (pt) | Agonistas não peptídicos do receptor de somatostatina tipo 5 e seus usos | |
| BR112018069515A2 (pt) | uso de masitinibe para tratamento de uma subpopulação de pacientes com esclerose lateral amiotrófica | |
| BRPI0510613A (pt) | cisteaminas para tratar complicações de hipercolesterolemia e diabete | |
| BR112022021964A2 (pt) | Ácidos nucleicos modificados que codificam aspartoacilase (aspa) e vetores para terapia gênica | |
| BR112022023545A2 (pt) | Polipeptídeo com atividade de cisteína protease de igg, polinucleotídeo, vetor de expressão, célula hospedeira, composição e métodos para a prevenção ou tratamento de uma doença ou condição e para a clivagem de igg ex vivo | |
| BRPI0600199A (pt) | usos de ácido pinolênico ou um seu derivado e de uma composição | |
| Borges-Martins et al. | Caffeine regulates GABA transport via A1R blockade and cAMP signaling | |
| BR112021024325A2 (pt) | Análogos de 3-(5-metil-1,3-tiazol-2-il)-n-{(1r)-1-[2-(trifluoro-metil)pirimidin-5-il]etil}benzamida | |
| DOP2024000147A (es) | Inhibidores de proteína tirosina fosfatasa y usos de estos | |
| Hu et al. | Microtubule-depolymerizing kinesins in the regulation of assembly, disassembly, and length of cilia and flagella | |
| JOP20230173A1 (ar) | أشطر إطالة العمر-النصفي وطرق استخدامها | |
| AR039895A1 (es) | Composicion que comprende una vitamina, una sal de metal y una insulina o una hormona del crecimiento y uso de dichos componentes para prepararla | |
| BR112019000991A2 (pt) | análogo da insulina, composição farmacêutica, método para tratar e/ou prevenir uma afeção relacionada com insulina, método para decrescer níveis de glicose no sangue, uso do análogo da insulina, método de replanejamento ou modificação de um polipeptídeo que é conhecido por se ligar a um receptor da insulina, polipeptídeo, molécula isolada, método para identificar um composto que se liga ao receptor de insulina, método de base computacional para identificar um composto que imita a atividade da insulina, composto identificado usando um método, cristal do polipeptídeo, estrutura do polipeptídeo, uso da estrutura, uso do modelo estrutural, peptídeo, método para aumentar a ativação do receptor da insulina em um sujeito, método para diminuir o açúcar no sangue em um sujeito, método para tratar diabetes tipo 1 em um sujeito e proteína terapêutica | |
| BR0211619A (pt) | Uso de pentraxina ptx3 longa para tratamento da infertilidade feminina | |
| BR112022001700A2 (pt) | Método para tratar doença de alzheimer regulando-se o nível de aminoácidos | |
| Ramió‐Lluch et al. | “In vitro” capacitation and further progesterone‐induced acrosome exocytosis are linked to specific changes in the expression and location of threonine phosphorylation of boar spermatozoa | |
| BR112023019520A2 (pt) | Implantes e métodos ortopédicos |